|
|
"A comprehensive, collaborative elections resource."
|
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask
|
|---|
| Parent(s) |
Issue
|
| Contributor | RP |
| Last Edited | RP Apr 13, 2018 08:11am |
| Logged |
0
|
| Category | Analysis |
| Author | Beth Mole |
| News Date | Thursday, April 12, 2018 10:45:00 PM UTC0:0 |
| Description | One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year. |
| Share |
|
|
2¢
|
|
| Article | Read Full Article |
|
| Date |
Category |
Headline |
Article |
Contributor |
|
|
